Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising
Wednesday, 17 April 2019 Paradigm Biopharmaceuticals Ltd (ASX:PAR) has secured $61.3 million in funding from the institutional component of its rights issue and placement priced at $1.50. An additional $16.6 million is expected to be raised through the retail component of the rights issue, which will open next Wednesday 24 April 2019. This will take the total capital raising to $77.9 million as outlined earlier to the market on Monday. READ: Paradigm Biopharmaceuticals raising $77.9 million to fund its pivotal phase 3 OA trial Paradigm’s managing director Paul Rennie said: “On behalf of the board we delighted with the overwhelmingly positive response to the release of the osteoarthritis phase 2B secondary endpoint data (on 15 April) and this capital raise. “The board believes that Paradigm has now secured funding for purposes including the conclusion of our pivotal phase 3 clinical trials for OA and MPS. New international investors on board “I take this opportunity to welcome new institutions from the UK, USA, Asia and Australia to the register and to thank our existing shareholders for their ongoing support. “From a clinical perspective I note the significance of the indicative regression of disease demonstrated by our secondary endpoint data. “With this combination of funding and compelling clinical data the company is well placed to progress its clinical program whilst pursuing potential commercial transactions.” READ: Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee On Monday this week, the company also revealed that it had successfully achieved the secondary endpoints of improved knee function and pain reduction for its phase 2b trial in OA of the knee.
President Donald Trump will run for re-election in the 2020 presidential campaign. His campaign said they raised more than $30 million in the first quarter of 2019. According to Reuters,Trump has outpaced the total raised by individual Democratic candidates for the quarter. The large amount of money...
Tilray said first-quarter revenue rose 195% from a year earlier to $23 million, as sales in Canada surged following the country's decision to legalize cannabis for recreational use. The adjusted loss..
Let's dive into the markets, Real Money's Stock of the Day Macy's and the cannabis sector. What's Going on in the Markets? After all of the trade news we've gotten this week, and the market reaction,..